CoChat

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons

Open access
Dalsgaard, Niels B., Vilsbøll, Tina, Knop, Filip K. · 2018 · Diabetes, Obesity and Metabolism
Cited by 54

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Cardiovascular (CV) disease is the leading cause of death and morbidity in patients with type 2 diabetes. Five CV risk factors (blood pressure, resting heart rate, body weight, cholesterol levels and blood glucose) are monitored routinely as safety and efficacy endpoints in randomized clinical trials for diabetes therapies. To determine if different glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) had varying effects on these CV risk factors, we reviewed 16 head‐to‐head trials directly comparing GLP‐1RAs that included at least one of the five factors. Few trials reported statistical differences between GLP‐1RAs in terms of systolic blood pressure (SBP), body weight and total cholesterol. Liraglutide increased heart rate vs its comparators in three separate trials. All GLP‐1RAs reduced glycated haemoglobin (HbA1c), but exenatide twice daily and lixisenatide had statistically smaller effects compared with other GLP‐1RAs. These descriptive data indicate that individual GLP‐1RAs affect CV risk factors differently, potentially because of their individual pharmacokinetics and/or size. Short‐acting GLP‐1RAs appeared to result in smaller changes in SBP and total cholesterol compared with continuous‐acting treatments, while large GLP‐1RAs had a reduced effect on body weight compared with small GLP‐1RAs. For glycaemic control, short‐acting GLP‐1RAs had a greater impact on postprandial glucose levels vs continuous‐acting GLP‐1RAs, but for fasting plasma glucose levels and HbA1c, continuous‐acting treatments had the greater effect. No differentiating trends were obvious in heart rate data. These diverse actions of GLP‐1RAs on CV risk factors should aid individualized patient treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13128

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 54

Metadata

Authors
Dalsgaard, N. B., Vilsbøll, T., & Knop, F. K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-11-08
Volume
20
Issue
3
Pages
508-519
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2763508675
Cited by
54
References
29
FWCI
1.00
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons. https://app.cochat.ai/papers/10.1111/dom.13128
The paper
Dalsgaard, N. B., Vilsbøll, T., & Knop, F. K. (2018). Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13128

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.